RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients

Stock Information for Redhill Biopharma Ltd.

Loading

Please wait while we load your information from QuoteMedia.